Research Topics
| Alan PollackSummaryAffiliation: Fox Chase Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?Alan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Nat Clin Pract Oncol 2:12-3. 2005
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trialAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 64:518-26. 2006..The dosimetry and acute toxicity are described in the first 100 men enrolled in a randomized trial...
Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202Arnab Chakravarti
Massachusetts General Hospital Harvard Medical School, Department of Radiation Oncology, Boston, MA 02114, USA
J Clin Oncol 25:3082-9. 2007..In the present study, we examined the prognostic value of p16 expression in men with locally advanced prostate cancer who were enrolled on Radiation Therapy Oncology Group protocol 9202...
The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapyMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 59:1383-91. 2004..Intensity-modulated radiation therapy may offer further reductions in the doses received by the PB and CB; however, at what cost to prostate coverage and normal tissue sparing will be the subject of a follow-up study...
MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02Li Yan Khor
Department of Radiation Oncology, University of Miami, Sylvester Comprehensive Cancer Center, 1475 NW 12th Ave, Suite 1501, Miami, FL 33130, USA
J Clin Oncol 27:3177-84. 2009..CONCLUSION Combined MDM2 and Ki-67 expression levels were independently related to distant metastasis and mortality and, if validated, could be considered for risk stratification of patients with prostate cancer in clinical trials...
The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02Alan Pollack
Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
Clin Cancer Res 15:5478-84. 2009..Here, we attempt to verify our prior findings and test the hypothesis that the relationship of the length of AD to patient outcome is affected by PKA(RIalpha) overexpression...
Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivoRadka Stoyanova
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 68:1151-60. 2007..To test the effects of antisense (AS)-MDM2 alone and with androgen deprivation (AD), radiotherapy (RT), and AD + RT on wild-type LNCaP cells in an orthotopic in vivo model...
Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancerMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 63:1455-62. 2005..To compare several characteristics of alternative definitions of biochemical failure (BF) in men with extended follow-up after radiotherapy (RT) with or with androgen deprivation therapy (ADT) for prostate cancer...
The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancerRojymon Jacob
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111-2497, USA
Cancer 100:538-43. 2004..CONCLUSIONS: Escalation of RT dose reduced the rates of BF, DM, and OM significantly in patients with prostate cancer. The inclusion of YOT had a pronounced effect on these correlations that may confound interpretation...
Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancerNiraj Pahlajani
Department of Radiation Oncology, Cooper University Hospital, Camden, NJ, USA
Int J Radiat Oncol Biol Phys 82:1949-56. 2012..However, local failure is also a major problem. We sought to establish the importance of more aggressive local radiotherapy (RT) to ≥80 Gy...
Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?Stephen F Andrews
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 104:299-304. 2005..There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes...
Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapySteven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 62:397-405. 2005..To determine whether the use of androgen deprivation (AD) increases late morbidity when combined with high-dose three-dimensional conformal radiation therapy (3D-CRT)...
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancerDeborah A Kuban
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 70:67-74. 2008..To report the long-term results of a randomized radiotherapy dose escalation trial for prostate cancer...
Comparing computed tomography localization with daily ultrasound during image-guided radiation therapy for the treatment of prostate cancer: a prospective evaluationSteven J Feigenberg
Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, Pennsylvania 19111, USA
J Appl Clin Med Phys 8:2268. 2007..The isocenter shifts generated by using a CT unit in the treatment room correlate highly with shifts produced by the BAT Ultrasound system...
Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvementRojymon Jacob
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 61:695-701. 2005..These data suggest that the primary tumor takes precedence over lymph node coverage or the use of STAD. Doses >70 Gy are of paramount importance in such intermediate- and high-risk patients...
Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivoZhaomei Mu
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Prostate 68:599-609. 2008..In this study, we investigated the effects of AS-MDM2 combined with AD on androgen resistant LNCaP (LNCaP-Res) and moderately androgen resistant bcl-2 overexpressing LNCaP (LNCaP-BST) cells...
A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implantThomas N Eade
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Int J Radiat Oncol Biol Phys 71:338-45. 2008..To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and (125)I transperineal permanent prostate seed implant ((125)I) for patients with low-risk prostate cancer...
What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?Steven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 61:1003-10. 2005..The purpose of this study was to determine what pretreatment (initial) PSA (iPSA) level, if any, warrants the addition of long-term androgen deprivation in the PSA era...
Does age matter in the selection of treatment for men with early-stage prostate cancer?Andre Konski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 106:2598-602. 2006....
What dose of external-beam radiation is high enough for prostate cancer?Thomas N Eade
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 68:682-9. 2007..To quantify the radiotherapy dose-response of prostate cancer, adjusted for prognostic factors in a mature cohort of men treated relatively uniformly at a single institution...
The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancerAlexandra L Hanlon
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 67:1082-7. 2007..To investigate the prognostic utility of the proportion of prostate biopsy tissue containing Gleason pattern 4 or 5 (GP4/5) after definitive radiotherapy (RT) for prostate cancer...
Hazards of dose escalation in prostate cancer radiotherapyDeborah Kuban
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 57:1260-8. 2003..To assess the benefit of escalating the dose in definitive prostate cancer radiotherapy vs. the associated risk of complications...
Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapyPeter B Morgan
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
Cancer 110:68-80. 2007..The authors hypothesized that early failures due to subclinical micrometastasis at presentation could be differentiated from late failures due to local persistence...
Radiation dose and late failures in prostate cancerPeter B Morgan
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Int J Radiat Oncol Biol Phys 67:1074-81. 2007..To quantify the impact of radiation dose escalation on the timing of biochemical failure (BF) and distant metastasis (DM) for prostate cancer treated with radiotherapy (RT) alone...
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancerEdouard J Trabulsi
Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Urology 72:1298-302; discussion 1302-4. 2008..We studied a group of patients undergoing ART by comparing them with a matched control group undergoing SRT after biochemical failure...
Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancerNavesh K Sharma
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 80:437-44. 2011..The present study compared the genitourinary and gastrointestinal (GI) toxicity in men treated with 3D-CRT+AD vs. IMRT+AD...
Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10Li Yan Khor
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 71:1309-15. 2008....
How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?David J D'Ambrosio
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 70:1487-91. 2008..This study sought to determine whether the initial PSA increase from undetectable after completion of all treatment predicts for eventual biochemical failure (BF)...
Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemopreventionPaul L Crispen
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Prostate 67:582-90. 2007..NF-kappaB and AP-1 transcriptional factors contribute to the development and progression of prostate malignancy by regulating the expression of genes involved in proliferation, apoptosis, angiogenesis, and metastasis...
Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancerAlexandra L Hanlon
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 58:43-52. 2004....
PKA knockdown enhances cell killing in response to radiation and androgen deprivationHarvey H Hensley
Basic Science Division, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Cancer 128:962-73. 2011..We demonstrate for the first time that AS-PKA enhances cell killing androgen sensitive prostate cancer cells to AD ± RT and androgen insensitive cells to RT...
Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancerDeborah Watkins Bruner
Department of Population Science, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 58:34-42. 2004..To assess the preferences and utilities for prostate cancer health state scenarios of men treated with three-dimensional conformal radiotherapy and the predictors of treatment preferences...
Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivationMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 61:1291-8. 2005..The American Society of Therapeutic Radiation Oncology definition for biochemical failure overestimates BF in 20-30% after RT+AD compared to 5% after RT alone...
Magnetic resonance-based treatment planning for prostate intensity-modulated radiotherapy: creation of digitally reconstructed radiographsLili Chen
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 68:903-11. 2007....
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trialMack Roach
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
Int J Radiat Oncol Biol Phys 69:79-87. 2007..To understand how variation in CYP3A4 correlated with outcomes, a retrospective examination of the CYP3A4 *1B genotype was performed on men treated with Radiation Therapy Oncology Group (RTOG) 92-02...
A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapyDerek B Chism
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111-2497, USA
Int J Radiat Oncol Biol Phys 59:380-5. 2004..CONCLUSIONS: The SF model created prognostic groups with a greater internal consistency than the DF model. The SF was also better at identifying patients with high-risk prostate cancer who may benefit from a more aggressive approach...
Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapyAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 57:19-23. 2003..However, little evidence is available to show that BF is associated with death for patents with prostate cancer treated with radiotherapy. We examined the relationship between BF and death from prostate cancer...
Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivationZhaomei Mu
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Prostate 60:187-96. 2004..Antisense MDM2 has broad potential as a therapeutic agent to sensitize prostate cancer cells to AD therapy by enhancing apoptotic cell death...
A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancerSteven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Am J Clin Oncol 29:458-62. 2006..The purpose of this report is to determine whether any specific magnitude in the prostate specific antigen (PSA) bounce predicted for a clinically poorer outcome...
Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivoThirupandiyur S Udayakumar
Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida, USA
Int J Radiat Oncol Biol Phys 79:549-58. 2011..Here, we demonstrate the radiosensitization efficacy of adenovirus (Ad)-E2F1 infection in growing (orthotopic) LNCaP and (subcutaneous) PC3 nude mice xenograft tumors...
A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostateRobert A Price
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 57:843-52. 2003..The focus of this work is to develop a practical planning method that results in increased dose conformity and reduced treatment time for segmental multileaf collimation (sMLC) based intensity-modulated radiation therapy (IMRT) delivery...
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trialLi Yan Khor
Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Lancet Oncol 8:912-20. 2007..We aimed to study COX-2 overexpression and outcome in a well-defined cohort of men who received treatment with short-term androgen deprivation (STAD) plus radiotherapy or long-term androgen deprivation (LTAD) plus radiotherapy...
Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapyMary Feng
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
Int J Radiat Oncol Biol Phys 68:1417-23. 2007..To determine the rate and magnitude of late genitourinary (GU) and gastrointestinal (GI) toxicities after salvage or adjuvant radiotherapy (RT) for prostate cancer, and to determine predictive factors for these toxicities...
Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?Andre Konski
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, USA
J Clin Oncol 25:3603-8. 2007..The specific aim of this study was to examine the cost effectiveness of proton beam radiation compared with current state-of-the art therapy in the treatment of patients with prostate cancer. Materials and..
Gains from real-time tracking of prostate motion during external beam radiation therapyJin sheng Li
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Int J Radiat Oncol Biol Phys 75:1613-20. 2009..To study the gains from real-time tracking of prostate motion and threshold-based intervention and the feasibility of margin reduction for external beam radiation therapy of prostate cancer...
Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?Deborah A Kuban
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 79:1310-7. 2011..To report long-term failure patterns and survival in a randomized radiotherapy dose escalation trial for prostate cancer...
Rectal dose variation during the course of image-guided radiation therapy of prostate cancerLili Chen
Radiation Oncology Department, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Radiother Oncol 95:198-202. 2010..To investigate the change in rectal dose during the treatment course for intensity-modulated radiotherapy (IMRT) of prostate cancer with image-guidance...
Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?Khanh H Nguyen
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 57:377-83. 2003....
Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and IIJeff M Michalski
Department of Radiation Oncology, Washington University, St Louis, MO 63110, USA
Int J Radiat Oncol Biol Phys 56:192-8. 2003..To evaluate the rates of low-grade late effects in patients treated for prostate cancer on Radiation Therapy Oncology Group (RTOG) 9406...
Positive prostate biopsy laterality and implications for stagingMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Urology 62:298-303. 2003..04). CONCLUSIONS: Inclusion of positive biopsy laterality status into clinical staging causes stage migration without reflecting a change in outcome and should not be used...
MR-guided pulsed high intensity focused ultrasound enhancement of docetaxel combined with radiotherapy for prostate cancer treatmentZhaomei Mu
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Phys Med Biol 57:535-45. 2012....
Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiationThirupandiyur S Udayakumar
Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Mol Cancer Res 6:1742-54. 2008..These findings show that the combination of Ad-E2F1 and AS-MDM2 significantly increases cell death in prostate cancer cells exposed to radiation and that this effect occurs in the presence or absence of AR and p53...
Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy aloneEric M Horwitz
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
J Urol 169:2153-7; discussion 2157-9. 2003..Additional analysis with large numbers of patients from multiple institutions is necessary to determine the point...
Does treatment duration affect outcome after radiotherapy for prostate cancer?David J D'Ambrosio
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 72:1402-7. 2008..In prostate cancer, the overall treatment time can be considerable, as can the potential for treatment breaks. We evaluated the effect of elapsed treatment time on outcome after RT for prostate cancer...
Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapyMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 70:59-66. 2008..The present study examined the clinical utility of the interval to biochemical failure (IBF) as a prognostic factor for distant metastasis (DM) and prostate cancer-specific mortality (PCSM) after radiotherapy...
Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatmentAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Urol Clin North Am 30:337-49, x. 2003..In summary, advances in radiation oncology have led to significant gains in prostate cancer control. Clinical prognostic factor-based patient selection is central to the optimization of outcome...
MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRTLili Chen
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 60:636-47. 2004....
Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02Li Yan Khor
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 13:3585-90. 2007..A follow-up investigation was carried out here in more contemporary high-risk men treated on Radiation Therapy Oncology Group 92-02 with STAD+RT or long-term AD+RT (LTAD+RT)...
Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?David J D'Ambrosio
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Urology 71:938-41. 2008..The purpose of this study was to determine whether a history of TURP is associated with increased biochemical failure (BF) after definitive radiotherapy for prostate cancer...
Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10Li-Yan Khor
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 66:25-30. 2006..The cohort examined was comprised of patients with locally advanced disease and it is possible that these markers may be of greater value in men with earlier-stage prostate cancer...
Role of radiotherapy in ductal (endometrioid) carcinoma of the prostateThomas N Eade
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 109:2011-5. 2007..This case series of 6 patients is the first to report the outcome of ductal carcinoma treated with external beam radiotherapy...
Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation studyDarren J Little
Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Urology 62:707-13. 2003..Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased...
The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancerMatthew C Abramowitz
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
Cancer 112:55-60. 2008..The objective of the current study was to compare ASTRO and Phoenix BF estimates as determinants of distant metastasis (DM), cause-specific mortality (CSM), and overall mortality (OM)...
Prostate cancer radiotherapy dose response: an update of the fox chase experienceAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
J Urol 171:1132-6. 2004....
Experience of ultrasound-based daily prostate localizationAnurag Chandra
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 56:436-47. 2003..Although the accuracy of the BAT was not addressed in this investigation, we found a significant percentage of large shifts being made from the initial alignment position...
Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findingsBenjamin Movsas
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Urology 60:634-9. 2002..The P/M PO2 ratio was the strongest predictor for biochemical control on stepwise multivariate analysis. Longer follow up with more patients is planned to confirm this result...
Treatment of prostate cancer with regional lymph node (N1) metastasisAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Semin Radiat Oncol 13:121-9. 2003..Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP...
Parameters for treatment decisions for salvage radiation therapyShelly Bowers Hayes
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
J Clin Oncol 23:8204-11. 2005..These factors should be used as a guide to the options of local therapy alone (RT), local therapy plus systemic therapy (typically androgen deprivation therapy), and systemic therapy alone...
Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancerEugene H Huang
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Int J Radiat Oncol Biol Phys 54:1314-21. 2002..Therefore, dose escalation may be safely achieved by adherence to dose-volume histogram constraints during treatment planning and organ localization at the time of treatment to ensure consistent patient setup...
Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-xAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 97:1630-8. 2003..The current study examined the association between expression levels of Ki-67, bcl-2, bax, and bcl-x in pretreatment biopsy specimens and patient outcome after definitive radiotherapy alone...
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trialAlan Pollack
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 53:1097-105. 2002..A randomized radiotherapy dose escalation trial was undertaken between 1993 and 1998 to compare the efficacy of 70 vs. 78 Gy in controlling prostate cancer...
MR-guided focused ultrasound: enhancement of intratumoral uptake of [³H]-docetaxel in vivoLili Chen
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Phys Med Biol 55:7399-410. 2010..Our data showed increased (³H-docetaxel concentration in the tumor in the MRgFUS-treated group (1079 ± 132 cmp/75 mg) versus those without MRgFUS treatment (524 ± 201 cmp/75 mg) with P = 0.037...
Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancerAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Urology 60:22-30; discussion 30-1. 2002..The results with long-term ADT are much more convincing than short-term ADT, and, as a consequence, 2 to 3 years are recommended...
Soft tissue sarcomas treated with postoperative external beam radiotherapy with and without low-dose-rate brachytherapyStephen F Andrews
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 59:475-80. 2004..On multivariate analysis, no predictors were found for better local control; however, the numbers of Stage III and high-grade patients were small, which may have masked a possible benefit of BT plus EBRT in this population...
Target localization for post-prostatectomy patients using CT and ultrasound image guidanceKamen Paskalev
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
J Appl Clin Med Phys 6:40-9. 2005..However, ultrasound alignments performed without the use of a template deteriorated patient positioning for two out of three patients, demonstrating that the use of a CT template was beneficial even at small initial displacements...
Radiation therapy dose escalation for prostate cancer: a rationale for IMRTAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
World J Urol 21:200-8. 2003..The results of dose escalation, the ability of IMRT to reduce rectal and bladder exposure to high radiation doses and the use of new imaging methods to more accurately target the prostate are described...
Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancerHoon K Lee
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
Int J Radiat Oncol Biol Phys 57:355-61. 2003..An alternative position for a surrogate urethra accounting for the difference in the location of the Foley catheter near the base of the prostate at Day 0 and 1 month could be considered in future studies...
Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancerAndre Konski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 66:408-15. 2006....
Influence of number of CAG repeats on local control in the RTOG 86-10 protocolMay Abdel-Wahab
Department of Radiation Oncology, University of Miami School of Medicine, Miami, FL 33136, USA
Am J Clin Oncol 29:14-20. 2006..The purpose of this study was to determine if short-term androgen deprivation therapy (RT + HT) can improve outcome in patients with tumors with short CAG repeats (<19)...
Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10Javier F Torres-Roca
Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
Urology 69:505-9. 2007....
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancerPeter R Carroll
Department of Urology, University of California School of Medicine, San Francisco, San Francisco, California, USA
Urology 60:1-6. 2002
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomyAndrew J Stephenson
Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
J Clin Oncol 25:2035-41. 2007..We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence...
Androgen suppression plus radiation therapy for prostate cancerEric M Horwitz
JAMA 292:2084-5; author reply 2085. 2004
Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancerCharles J Rosser
Department of Urology, The University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA
J Urol 168:2001-5. 2002..The PSA bounce phenomenon was not predictive of time to biochemical recurrence...
A call for more with a desire for less: pelvic radiotherapy with androgen deprivation in the treatment of prostate cancerAlan Pollack
J Clin Oncol 21:1899-901. 2003
Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202Mingxin Che
Department of Pathology, Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
Int J Radiat Oncol Biol Phys 69:1117-23. 2007....
Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapyDidier Cowen
Department of Experimental Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
Clin Cancer Res 8:1148-54. 2002..This prognostic factor was equally valuable for patients diagnosed by TURP or needle biopsy...
Is intraoperative nomogram-based overplanning of prostate implants necessary?WARREN D D'SOUZA
Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 56:462-7. 2003..Several investigators have described intraoperative planning of prostate implants based on a nomogram. The aim of this work was to investigate the adequacy of the nomogram in predicting the total activity necessary for optimal dosimetry...
Longitudinal associations among quality of life and its predictors in patients treated for prostate cancer: the moderating role of ageMichael Diefenbach
Urology and Oncological Sciences, Mount Sinai School of Medicine, New York, NY10029 6574, USA
Psychol Health Med 13:146-61. 2008..Among older patients (>68 years old, n = 192), lower levels of distress were associated with higher levels of functional QOL, and longer expected survival time was associated with better functional and physical QOL...
Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostateCharles J Rosser
Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
J Urol 169:2160-5. 2003..Patients are at slight but persistent risk for biochemical failure more than 5 years after treatment. Hazard rate calculations beyond the median followup of 4 years can underestimate the true hazard...
